<DOC>
	<DOCNO>NCT02055911</DOCNO>
	<brief_summary>To evaluate safety intravitreal ranibizumab repeat injection patient diabetic macular edema regard maintenance retinal ganglion cell function .</brief_summary>
	<brief_title>Retinal Ganglion Cell Function After Intravitreous Ranibizumab Patients With Diabetic Macular Edema</brief_title>
	<detailed_description>- Ranibizumab safe treatment diabetic macular edema regard maintenance retinal ganglion cell function repeat intravitreal injection . - To evaluate safety intravitreal ranibizumab repeat injection patient diabetic macular edema regard maintenance retinal ganglion cell function . - The primary endpoint study change full-field focal macular photopic negative response ( PhRN ) amplitude ( ÂµV ) time , baseline month 12 .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ganglion Cysts</mesh_term>
	<mesh_term>Synovial Cyst</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female patient , old 18 year , sign informed consent . Patients Type 1 Type 2 diabetes mellitus prior diagnosis diabetic macular edema ( DME ) , undergone previous treatment , either pharmacological laser photocoagulation . Patients visual impairment due DME , opinion investigator , would benefit treat IVR . Known hypersensitivity ranibizumab component . Previous participation clinical study investigational drug within 1 month Women childbearing potential , defined woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS use two birth control method . The two method double barrier method barrier method plus hormonal method . Adequate barrier method contraception include : diaphragm , condom ( partner ) , intrauterine device ( copper hormonal ) , sponge spermicide . Hormonal contraceptive include market contraceptive agent include estrogen and/or progestational agent . Pregnant nursing ( lactate ) woman . Inability comply study followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>diabetic macular edema</keyword>
	<keyword>intravitreal ranibizumab</keyword>
	<keyword>f retinal ganglion cell</keyword>
</DOC>